Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Mesoblast Ltd Ads (MESO)

Mesoblast Ltd Ads (MESO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 458,613
  • Shares Outstanding, K 94,171
  • Annual Sales, $ 17,340 K
  • Annual Income, $ -35,290 K
  • 60-Month Beta 1.84
  • Price/Sales 27.86
  • Price/Cash Flow N/A
  • Price/Book 0.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.23
  • Number of Estimates 2
  • High Estimate -0.22
  • Low Estimate -0.25
  • Prior Year -0.22
  • Growth Rate Est. (year over year) -4.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.58 +3.93%
on 08/06/19
5.40 -11.85%
on 07/26/19
-0.61 (-11.36%)
since 07/23/19
3-Month
4.58 +3.93%
on 08/06/19
6.03 -21.06%
on 06/25/19
-0.30 (-5.93%)
since 05/23/19
52-Week
3.35 +42.09%
on 12/24/18
8.78 -45.79%
on 10/01/18
-1.16 (-19.59%)
since 08/23/18

Most Recent Stories

More News
Remestemcel-L to be Evaluated as Treatment for Chronic Graft Versus Host Disease in Planned Investigator-Initiated Trial

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that it intends to provide its allogeneic cell therapy product candidate remestemcel-L...

MESO : 4.77 (-2.05%)
Mesoblast Appoints Leading Pharmaceutical Industry Executive as Chief Medical Officer

Mesoblast Limited (Nasdaq: MESO; ASX: MSB), global leader in cellular medicines for inflammatory diseases, is pleased to announce the appointment of Dr Fred Grossman as Chief Medical Officer (CMO), based...

MESO : 4.77 (-2.05%)
JNJ : 127.73 (-2.70%)
LLY : 109.51 (-1.88%)
Mesoblast Quarterly Cash Flow Report

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today reported its operational highlights and its quarterly cash flows for the fourth quarter (fourth quarter FY2019) and 12 months ended June 30, 2019 (FY2019)....

MESO : 4.77 (-2.05%)
Pain Relief Therapeutics Market 2019 Industry Analysis and Opportunities by Top Key Players are Novartis AG, Eli Lilly & Company, Abbott Laboratories, Endo Health Solutions Inc., Purdue Pharma L.P.

: The rising prevalence of chronic diseases such as a variety of cancers, osteoarthritis, stomach ulcer, chronic arthritis and diabetes are major key factor which drives the Global Pain Relief Therapeutics...

ORXOY : 7.3000 (-11.52%)
BAYRY : 18.4400 (-2.33%)
BDSI : 4.28 (-3.17%)
MRK : 84.94 (-2.05%)
EGLT : 0.0315 (-63.37%)
NVS : 88.44 (-0.63%)
PFE : 34.34 (-2.11%)
AXSM : 24.85 (-1.51%)
MESO : 4.77 (-2.05%)
BDRFF : 122.7767 (+1.34%)
ABT : 81.93 (-2.89%)
LLY : 109.51 (-1.88%)
ACOR : 3.12 (-1.89%)
FLXN : 11.07 (-0.36%)
DEPO : 7.30 (+1.67%)
NKTR : 16.99 (+0.06%)
VRX.TO : 30.80 (-3.33%)
BMY : 46.58 (-2.67%)
HRTX : 17.38 (-3.87%)
SRNE : 2.10 (-6.67%)
COLL : 11.34 (-3.90%)
DRRX : 1.57 (+2.61%)
ACRX : 2.20 (-2.22%)
KMPH : 0.89 (+23.61%)
REGN : 286.85 (-2.77%)
GLPG : 162.97 (-1.87%)
Circulation Research Special Article Highlights Potential Of Mesoblast Cell Therapy In Treatment Of Advanced Heart Failure

Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today announced that premier cardiovascular journal Circulation Research has published a Special Article highlighting the important potential clinical benefits...

MESO : 4.77 (-2.05%)
Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Designation From FDA for Prevention of Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices

Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, announced today that the United States Food and Drug Administration (FDA) has granted the company's...

MESO : 4.77 (-2.05%)
Mesoblast Starts Rolling BLA Submission for Remestemcel-L

Mesoblast (MESO) begins the rolling submission of a BLA for its lead product, candidate remestemcel-L, to the FDA for treating children with steroid-refractory acute graft versus host disease.

MESO : 4.77 (-2.05%)
RGEN : 90.86 (-1.94%)
INCY : 81.91 (-4.27%)
ACOR : 3.12 (-1.89%)
Mesoblast to Present at 2019 RBC Capital Markets Global Healthcare Conference

Mesoblast Limited (Nasdaq: MESO; ASX: MSB), global leader in cellular medicines for inflammatory diseases, today announced an upcoming corporate presentation to the 2019 RBC Capital Markets Healthcare...

MESO : 4.77 (-2.05%)
Detailed Research: Economic Perspectives on Advanced Micro Devices, Syros Pharmaceuticals, La Jolla Pharmaceutical, Integer, Mesoblast, and InnerWorkings -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Advanced Micro Devices,...

SYRS : 10.83 (unch)
MESO : 4.77 (-2.05%)
LJPC : 10.36 (+1.37%)
ITGR : 72.59 (-4.73%)
AMD : 29.54 (-7.40%)
INWK : 4.56 (-2.77%)
Mesoblast to Present at Upcoming Global Life Sciences Conference in London

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced an upcoming corporate presentation by the company at the H.C. Wainwright Global...

MESO : 4.77 (-2.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade MESO with:

Business Summary

Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's...

See More

Key Turning Points

2nd Resistance Point 5.00
1st Resistance Point 4.93
Last Price 4.77
1st Support Level 4.83
2nd Support Level 4.80

See More

52-Week High 8.78
Fibonacci 61.8% 6.71
Fibonacci 50% 6.06
Fibonacci 38.2% 5.42
Last Price 4.77
52-Week Low 3.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar